evelo-logo.png
Evelo Biosciences Announces Dosing of First Patient in Phase 1/2 Clinical Trial of EDP1503 in Combination with KEYTRUDA® (pembrolizumab) in Multiple Oncology Indications
January 04, 2019 06:00 ET | Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Jan. 04, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO) (“Evelo”) a biotechnology company developing monoclonal microbials, a new modality of oral biologic...
evelo-logo.png
Evelo Biosciences to Present at BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference
December 05, 2018 08:00 ET | Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Dec. 05, 2018 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”),  a clinical-stage biotechnology company developing monoclonal microbials to engage immune cells...
evelo-logo.png
Evelo Enters into Clinical Trial Collaboration Agreement with Merck
November 27, 2018 08:00 ET | Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO) (“Evelo”), a clinical-stage biotechnology company developing monoclonal microbials to engage immune cells in...
evelo-logo.png
Evelo Biosciences Announces First Dosing in Phase 1b Clinical Trial of EDP1815 in Psoriasis and Atopic Dermatitis
November 26, 2018 08:00 ET | Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO) (“Evelo”) a clinical-stage biotechnology company developing monoclonal microbials to engage immune cells in...
evelo-logo.png
Evelo Biosciences to Present at Upcoming Investor Conferences in November
November 07, 2018 08:00 ET | Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a clinical stage biotechnology company developing monoclonal microbials designed to act on the...
evelo-logo.png
Evelo Biosciences Reports Third Quarter 2018 Financial Results and Recent Business Highlights
November 01, 2018 08:00 ET | Evelo Biosciences, Inc.
-- Approval to Initiate Phase 1b Trial of EDP1815 in Psoriasis and Atopic Dermatitis: Dosing of First Patient Expected in 4Q18 ---- Initiation of Investigator-Sponsored Phase 2a Trial of EDP1503 in...
evelo-logo.png
Evelo Biosciences to Present at the Morgan Stanley 16th Annual Global Healthcare Conference
September 06, 2018 08:00 ET | Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Sept. 06, 2018 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a clinical stage biotechnology company developing monoclonal microbials designed to act on the...
evelo-logo.png
Evelo Biosciences Reports Second Quarter 2018 Financial Results and Recent Business Highlights
August 02, 2018 08:00 ET | Evelo Biosciences, Inc.
-- Advancing Multiple Product Candidates into Clinical Trials with Dosing of First Patient in Phase 1 Trial of EDP1066 in Psoriasis and Atopic Dermatitis and FDA Acceptance of IND for Phase 2a...
evelo-logo.png
Evelo Biosciences Added To Russell 3000®, 2000® and Microcap® Indexes
June 25, 2018 08:00 ET | Evelo Biosciences, Inc.
CAMBRIDGE, Mass., June 25, 2018 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company pioneering monoclonal microbials designed to act on the gut-body...
evelo-logo.png
Evelo Biosciences to Present at the JMP Securities 2018 Life Sciences Conference
June 14, 2018 08:00 ET | Evelo Biosciences, Inc.
CAMBRIDGE, Mass., June 14, 2018 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company pioneering monoclonal microbials designed to act on the gut-body...